Is Cerebrolysin FDA approved?

Cerebrolysin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

P21 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cerebrolysin administered in research settings?

In research settings, Cerebrolysin is typically administered via the intravenous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

How is P21 administered in research settings?

In research settings, P21 is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerebrolysin vs P21

Peptide Comparison

Cerebrolysin vs P21

Name: Cerebrolysin vs P21 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Neuro & Cognitive peptides.

Cerebrolysin

FPF 1070

CognitiveInvestigationalResearch Only

Half-life: Varies by component

33 providers listed

Full Cerebrolysin profile →

P21

CNTF fragment

CognitiveNot EvaluatedResearch Only

Half-life: Unknown

5 providers listed

Full P21 profile →

Bottom line

Cerebrolysin carries stronger published evidence (Meta-analysis, 5 key studies) than P21 (Animal, 2); both are research compounds.

Quick Verdict

Cerebrolysin

P21

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cerebrolysin
Further along in FDA review	Cerebrolysin
More provider options (33 vs 5)	Cerebrolysin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerebrolysin

P21

Mechanism Family

Neuro & Cognitive

Half-life

Varies by component

Unknown

FDA Status

investigational

not evaluated

Admin Routes

intravenous, intramuscular

subcutaneous, intranasal

Availability

Research Only

Providers

33 listed

5 listed

Avail. Notes

Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.

CNTF-derived pentapeptide fragment studied for cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Very limited human research. Research compound.

Research Evidence

Cerebrolysin

Meta-analysis · 5 key studies · most recent 2026

P21

Animal · 2 key studies · most recent 2017

Research Citations

Cerebrolysin

Meta-analysis2019 · Cochrane Database of Systematic Reviews

Cerebrolysin for vascular dementia

Cohort2026 · Asian J Neurosurg

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Mon…

RCT2024 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a thre…

In vitro2026 · Cells

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothel…

+1 more

P21

Animal2017 · Journal of Alzheimer's Disease

Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Tre…

Animal2010 · FEBS Letters

Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic…

About Cerebrolysin

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Research Areas

neuroprotectionneuroplasticitymemory improvementcognitive recovery

About P21

Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

Research Areas

neurogenesisBDNF upregulationmemory enhancementneuroprotection

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerebrolysin

Reported (Unverified — Pending Clinical Review)

epilepsyrenal failureporcine protein allergy

No established clinical contraindications

P21

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Cerebrolysin

$0.83/mg

$0.82 – $0.83 range

9 vendors

View price index →Find providers →

P21

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cerebrolysin

33 listed

Browse directory →

Providers offering

P21

5 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cerebrolysin vs P21 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cerebrolysin/p21

https://peptidebase.io/peptides/compare/cerebrolysin/p21 Methodology License Download JSON Download CSV